Indication
Solid Tumors with KRAS p.G12C Mutation
1 clinical trial
1 product
Product
AMG 510Clinical trial
A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 105)Status: Active (not recruiting), Estimated PCD: 2021-12-31